Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. | Clin Cancer Res;13(10): 3006-14, 2007 May 15. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.

Zinner, Ralph G; Nemunaitis, John; Eiseman, Irene; Shin, Hyung Ju C; Olson, Stephen C; Christensen, James; Huang, Xin; Lenehan, Peter F; Donato, Nicholas J; Shin, Dong M.

Affiliation

Zinner RG; M. D. Anderson Cancer Center, Houston, Texas, USA.

Clin Cancer Res ; 13(10): 3006-14, 2007 May 15.

Article in En | MEDLINE | ID: mdl-17505003

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Morpholines / Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2007 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Morpholines / Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2007 Document type: Article Affiliation country: Country of publication: